Making the Grade

There are thousands of stocks out there to choose from, but in order to build long-lasting wealth, you have to invest in the right ones. So how do professional investors sort the best opportunities from the worst? Our “Making the Grade” column ranks and compares companies based on key fundamental and technical metrics… ultimately making profitable investing easier and simpler.

Making the Grade

8 Ways to Play the Stock Market Meltdown

Here’s how to play the stock market meltdown to your advantage.

Making the Grade

Coronavirus Outbreak Stocks Are Crashing

The coronavirus outbreak stocks that skyrocketed during initial news of the epidemic are now falling.

Making the Grade

How to Book Gains Amid the Coronavirus Outbreak

The Wuhan coronavirus is the latest outbreak weighing on investors’ minds​.​ Here’s how to profit from it.

Making the Grade

10 Microcap Stocks Wall Street Believes Offer 200% Upside

Most microcaps are lagging the larger indexes, but some offer an upside of more than 200%.

Making the Grade

10 Stock Alternatives to Help Protect Your Portfolio in 2020

Here are 10 ETFs to help investors diversify their portfolios, reduce their overall volatility and potentially increase their returns in 2020.

Making the Grade

Is the Party Over? Here Are 10 Stocks to Avoid Now

Let’s look at some companies that are flying high right now… but might see their wings clipped soon.

Making the Grade

The Best Stocks From the Last 10 Years

The more than decade-old bull market transformed broader indexes and individual stocks into big-time winners.

Making the Grade

Top Microcap Stocks for 2020

Though microcaps and nanocaps carry considerably more volatility than their larger brethren, these 10 with quadruple-digit revenue growth are worth a look.

Making the Grade

10 Small Caps With Triple-Digit Revenue Growth

Investors are wary right now. That means there are small companies with tremendous upside and growth potential… trading at huge discounts.

Making the Grade

Most Overvalued Biotech Stocks in 2019

These biotech trailblazers are revolutionizing new treatments or curing diseases… and they’re extremely overvalued.